WHO ICTRP trial
To compare combination of study with marketed other combination of drug in…
CTRI/2022/11/047050 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2022/11/047050 |
|---|---|
| Public title | To compare combination of study with marketed other combination of drug in patients having both anxiety and depression. |
| Scientific title | A Phase IV study to evaluate the safety and efficacy of Placida® [Fixed Dose Combination of Flupentixol 0.5 mg + Melitracen 10 mg] in comparison to Escitalopram 10 mg + Clonazepam 0.5 mg in patients with comorbid anxiety and depression. |
| Primary sponsor | Mankind Pharma Limited |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | PMS |
| Phase | Post Marketing Surveillance |
| Countries | India |
| Conditions | Health Condition 1: F418- Other specified anxiety disorders |
| Interventions | Intervention1: FDC of Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) plus Melitracen 10 mg (as 11.25 mg melitracen hydrochloride): 2 tablets daily: morning and noon in the 1st week followed by a single tablet thereafter for 24… |
| Registration date | Apr 11, 2022 |
| Target size | 440 |
| Secondary IDs | CRB/CT-001/2018, Version 3.1, Dated: 01.12.2020 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: